Novo Nordisk A/S 2009 AR2
The report highlights Novo Nordisk's financial and non-financial performance for 2009, emphasizing value creation through innovation. The company achieved a 12% increase in sales, driven by its modern insulin portfolio, and successfully launched Victoza, a once-daily human GLP-1 analogue, in Europe. On environmental targets, the company decoupled greenhouse gas emissions from business growth, achieving a 31% reduction in CO2 emissions compared to the 2004 baseline. Additionally, the company expanded its social initiatives, including the Changing Diabetes in Children programme and the adoption of its differential pricing policy in 36 least developed countries.
Company: Novo Nordisk A/S
Sector: Manufacturing
Country: Denmark
Year: 2009
Type: AR2
Pages: 112
Back to company
Novo Nordisk A/S
Annual Report
The report highlights Novo Nordisk's financial and non-financial performance for 2009, emphasizing value creation through innovation. The company achieved a 12% increase in sales, driven by its modern insulin portfolio, and successfully launched Victoza, a once-daily human GLP-1 analogue, in Europe. On environmental targets, the company decoupled greenhouse gas emissions from business growth, achieving a 31% reduction in CO2 emissions compared to the 2004 baseline. Additionally, the company expanded its social initiatives, including the Changing Diabetes in Children programme and the adoption of its differential pricing policy in 36 least developed countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Jan 1, 2009 - Dec 31, 2009
Fiscal Year
2009
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees